Literature DB >> 26670198

Predictive factors of pathological vascular invasion in hepatocellular carcinoma within 3 cm and three nodules without radiological vascular invasion.

Toshiro Masuda1,2, Toru Beppu1, Hirohisa Okabe1, Hidetoshi Nitta1, Katsunori Imai1, Hiromitsu Hayashi1, Akira Chikamoto1, Kenichiro Yamamoto2, Satoshi Ikeshima2, Masafumi Kuramoto2, Shinya Shimada2, Hideo Baba1.   

Abstract

AIM: The aim of this study was to determine the predictive factors of pathological vascular invasion as contra-indicators for ablation therapy in patients with hepatocellular carcinoma (HCC) within 3 cm and three nodules without radiological vascular invasion.
METHODS: Two hundred and seventeen patients with HCC within 3 cm and three nodules without radiological vascular invasion who underwent hepatic resection were retrospectively investigated.
RESULTS: Pathological vascular invasion was positive in 46 patients, consisting of 38 portal vein invasions, three hepatic vein invasions, two hepatic artery invasions, one hepatic duct invasion and two with portal and hepatic vein invasions. In univariate analysis, patients with α-fetoprotein (AFP) of more than 100 ng/mL had higher rates of pathological vascular invasion than those without. In addition, patients with protein induced by vitamin K absence (PIVKA-II) of more than 100 mAU/mL had higher rates of pathological vascular invasion than those without. Multivariate analysis revealed that AFP of more than 100 ng/mL and PIVKA-II of more than 100 mAU/mL were independent predictive factors for pathological vascular invasion. As these patients were treated with hepatic resection, cumulative 5-year recurrence-free and overall survivals were not significantly different between the pathological vascular invasion negative and positive cases.
CONCLUSION: AFP of more than 100 ng/mL and PIVKA-II of more than 100 mAU/mL can predict pathological vascular invasion in patients with HCC within 3 cm and three nodules without radiological vascular invasion. In treating such cases, hepatic resection rather than local ablation therapy is recommended.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  ablation therapy; hepatocellular carcinoma; pathological vascular invasion

Year:  2016        PMID: 26670198     DOI: 10.1111/hepr.12637

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  9 in total

1.  Clinical factors that affect the outcomes after anatomical versus non-anatomical resection for hepatocellular carcinoma.

Authors:  Takehito Yamamoto; Shintaro Yagi; Kenji Uryuhara; Satoshi Kaihara; Ryo Hosotani
Journal:  Surg Today       Date:  2016-08-08       Impact factor: 2.549

2.  Microscopic vascular invasion by hepatocellular carcinoma in liver transplant patients.

Authors:  Brian I Carr; Volkan Ince; Harika Gozukara Bag; Veysel Ersan; Sertac Usta; Sezai Yilmaz
Journal:  Clin Pract (Lond)       Date:  2020

3.  Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Xiao-Lu Ma; Jing Zhu; Jiong Wu; Lu Tian; Yao-Yi Gao; Chun-Yan Zhang; Yan Zhou; Qian Dai; Bei-Li Wang; Bai-Shen Pan; Jian Zhou; Jia Fan; Xin-Rong Yang; Wei Guo
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

Review 4.  Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma.

Authors:  Yang Yang; Guangbing Li; Ziwen Lu; Yong Liu; Junjie Kong; Jun Liu
Journal:  Front Oncol       Date:  2021-11-10       Impact factor: 6.244

5.  CD86⁺/CD206⁺, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis.

Authors:  Pingping Dong; Lijie Ma; Longzi Liu; Guangxi Zhao; Si Zhang; Ling Dong; Ruyi Xue; She Chen
Journal:  Int J Mol Sci       Date:  2016-03-01       Impact factor: 5.923

6.  CAPS1 Negatively Regulates Hepatocellular Carcinoma Development through Alteration of Exocytosis-Associated Tumor Microenvironment.

Authors:  Ruyi Xue; Wenqing Tang; Pingping Dong; Shuqiang Weng; Lijie Ma; She Chen; Taotao Liu; Xizhong Shen; Xiaowu Huang; Si Zhang; Ling Dong
Journal:  Int J Mol Sci       Date:  2016-09-27       Impact factor: 5.923

7.  Microvascular invasion of single small hepatocellular carcinoma ≤3 cm: Predictors and optimal treatments.

Authors:  Yo-Ichi Yamashita; Katsunori Imai; Toshihiko Yusa; Yosuke Nakao; Yuki Kitano; Shigeki Nakagawa; Hirohisa Okabe; Akira Chikamoto; Takatoshi Ishiko; Tomoharu Yoshizumi; Shinichi Aishima; Yoshihiko Maehara; Hideo Baba
Journal:  Ann Gastroenterol Surg       Date:  2018-01-08

8.  The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.

Authors:  Fei Xu; Lulu Zhang; Wenting He; Di Song; Xiaomeng Ji; Jianyong Shao
Journal:  Dis Markers       Date:  2021-02-08       Impact factor: 3.434

9.  Integrated profiling identifies ITGB3BP as prognostic biomarker for hepatocellular carcinoma.

Authors:  Qiuli Liang; Chao Tan; Feifei Xiao; Fuqiang Yin; Meiliang Liu; Lei Lei; Liuyu Wu; Yu Yang; Hui Juan Jennifer Tan; Shun Liu; Xiaoyun Zeng
Journal:  Bosn J Basic Med Sci       Date:  2021-12-01       Impact factor: 3.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.